Benchmark initiated coverage of Prenetics Global Limited with a Buy rating and a $30 price target, citing the company's IM8 health and wellness brand and its position in the nutritional supplements market. The firm noted Prenetics is positioned for long-term growth through broader product offerings, expansion into related categories, diversification of marketing channels, and increasing international market penetration. Prenetics reported first quarter 2026 total revenue of $36.0 million, including $33.8 million from IM8, and raised its full-year 2026 IM8 revenue outlook to between $190 million and $210 million. The company also completed the sale of its digital asset holdings, generating $41.3 million in proceeds, and plans to introduce three new IM8 products in the fourth quarter of 2026.
Prenetics Global LtdAnalyst initiation with Buy rating and $30 PT, plus raised revenue guidance and completed asset sale.